World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 12 December 2020
Main ID:  NCT02555813
Date of registration: 18/09/2015
Prospective Registration: No
Primary sponsor: Celgene
Public title: Treatment of Pancreatic Cancer With Abraxane
Scientific title: Multicenter Non-interventional Study to Investigate Safety, Tolerability and Efficacy of Nab-paclitaxel in Clinical Routine Treatment of First-line Pancreatic Cancer Patients
Date of first enrolment: May 8, 2015
Target sample size: 317
Recruitment status: Completed
URL:  https://clinicaltrials.gov/show/NCT02555813
Study type:  Observational
Study design:   
Phase: 
Countries of recruitment
Austria
Contacts
Name:     Guenter Voraberger, MD
Address: 
Telephone:
Email:
Affiliation:  Celgene Austria
Key inclusion & exclusion criteria

Inclusion Criteria:

1. Metastatic pancreatic carcinoma

2. Age > 18 years

3. Signed Informed Consent

4. Normal hepatic, renal and Bone Marrow functions

Exclusion Criteria:

1. Pregnant and lactating females 2. Previous treatment for metastatic pancreatic disease
3. Known hypersensitivity to nab-paclitaxel 4. Neutrophils < 1,5 x 10^9/L

-



Age minimum: 18 Years
Age maximum: N/A
Gender: All
Health Condition(s) or Problem(s) studied
Metastatic Pancreatic Cancer
Intervention(s)
Drug: Abraxane
Drug: Gemcitabine
Primary Outcome(s)
Number of participants with adverse events [Time Frame: Up to 5 years]
Secondary Outcome(s)
Best Overall Response [Time Frame: Up to 5 years]
Secondary ID(s)
ABI-007-PANC-006
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history